A randomized, single-blind, placebo-controlled, dose-escalation phase I study to evaluate safety, pharmacological characteristics and pharmacokinetics of NC-2500 in healthy volunteers with single and multiple dosing.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs NC-2500 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- 01 Dec 2017 New trial record